Crenigacestat - Eli Lilly

Drug Profile

Crenigacestat - Eli Lilly

Alternative Names: JSMD194; LY-3039478

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Fred Hutchinson Cancer Research Center; National Cancer Institute (USA)
  • Class Antineoplastics; Benzazepines; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Phase I Cancer; Multiple myeloma; Solid tumours
  • Preclinical Hepatocellular carcinoma
  • No development reported Lymphoma

Most Recent Events

  • 20 Jun 2018 Phase-I clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03502577)
  • 18 Apr 2018 Fred Hutchinson Cancer Research Center in collaboration with National Cancer Institute plans a phase I trial for Multiple Myeloma in USA , (NCT03502577)
  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top